GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MyunMoon Pharm Co Ltd (XKRX:017180) » Definitions » Net Income

MyunMoon Pharm Co (XKRX:017180) Net Income : ₩-6,322 Mil (TTM As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is MyunMoon Pharm Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. MyunMoon Pharm Co's Net Income for the three months ended in Mar. 2024 was ₩-1,214 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-6,322 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. MyunMoon Pharm Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₩-37.00.


MyunMoon Pharm Co Net Income Historical Data

The historical data trend for MyunMoon Pharm Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MyunMoon Pharm Co Net Income Chart

MyunMoon Pharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20,402.08 -27,638.59 -6,864.50 7,867.99 -4,524.84

MyunMoon Pharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 582.68 -136.94 -938.90 -4,031.68 -1,213.99

MyunMoon Pharm Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

MyunMoon Pharm Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-4781.634+-92.609+0+349.406
=-4,525

MyunMoon Pharm Co's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2115.657+702.752+0+198.916
=-1,214

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-6,322 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MyunMoon Pharm Co  (XKRX:017180) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

MyunMoon Pharm Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


MyunMoon Pharm Co Net Income Related Terms

Thank you for viewing the detailed overview of MyunMoon Pharm Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


MyunMoon Pharm Co (XKRX:017180) Business Description

Traded in Other Exchanges
N/A
Address
946-18 Dokok-Dong, Kangnam-ku, Seoul, KOR, 135-270
MyunMoon Pharm Co Ltd is a South Korea based company engages in the manufacture and sale of pharmaceutical products. Its products include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs, and others.

MyunMoon Pharm Co (XKRX:017180) Headlines

No Headlines